ITGA4: Integrin alpha-4
Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ITGA4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| UCB-1184197 | Phase 2 | UCB Pharma | Small molecule | InhibitorIntegrin alpha-4 inhibitor | 0 |
- Crohn disease0.72
- Ulcerative colitis0.60
- Inflammatory bowel disease0.58
- Retinitis pigmentosa 260.52
- Neurodegenerative disease0.45
- Inherited retinal dystrophy0.38
- Hypothyroidism0.38
- Inflammation0.37
- Functional neutrophil defect0.36
- Decreased total leukocyte count0.36
- Isolated macular dystrophy0.34
- Cone-rod dystrophy0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL278, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P13612, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets